🔗 Share this article The Global Health Body Issues Alert Over Acute Scarcity of Weight-Loss Jabs Fewer than a tenth of individuals that would benefit from obesity jabs such as Wegovy are able to get them, states the WHO as it releases its initial guidance on the drugs. With more than one billion people worldwide currently living with obesity, it is advocating for broader and more equitable availability to this class of drugs. Based on forecasts, more than two billion will be obese by 2030 unless action is taken. "Our latest guidance recognises that obesity is a chronic disease that can be treated with holistic and lifelong treatment," said its chief Tedros Adhanom Ghebreyesus. Significant expense, insufficient output, and logistical bottlenecks are key hurdles to universal availability to the injections that can assist patients in reducing considerable weight, notes the organization. Weight-Loss Drug Supply Crisis Even in the current most favorable outlook, the manufacturing of GLP-1 therapies would only suffice for approximately 100 million people – under 10% of eligible patients, per the health organization. The recommendation calls on governments and firms to increase availability, via approaches like licensing agreements. Exclusive production rights on a key compound – the primary ingredient of Novo Nordisk's Wegovy – is set to lapse in multiple countries in 2026. The Way Obesity Injections Work These medications mimick a biological compound to slow digestion, curb appetite and increase satiety so people reduce food intake. Patients usually see weight reduction in the initial weeks of beginning the weekly injections. Evidence indicates users may regain a significant portion a year later of halting the medication, when their usual appetite come back. Being carrying excess weight increases your likelihood for experiencing diseases, such as type 2 diabetes, cardiovascular issues, brain attack, and certain cancers. Obesity affects people in all nations and was linked to millions of fatalities worldwide in 2024, per the health agency.
Fewer than a tenth of individuals that would benefit from obesity jabs such as Wegovy are able to get them, states the WHO as it releases its initial guidance on the drugs. With more than one billion people worldwide currently living with obesity, it is advocating for broader and more equitable availability to this class of drugs. Based on forecasts, more than two billion will be obese by 2030 unless action is taken. "Our latest guidance recognises that obesity is a chronic disease that can be treated with holistic and lifelong treatment," said its chief Tedros Adhanom Ghebreyesus. Significant expense, insufficient output, and logistical bottlenecks are key hurdles to universal availability to the injections that can assist patients in reducing considerable weight, notes the organization. Weight-Loss Drug Supply Crisis Even in the current most favorable outlook, the manufacturing of GLP-1 therapies would only suffice for approximately 100 million people – under 10% of eligible patients, per the health organization. The recommendation calls on governments and firms to increase availability, via approaches like licensing agreements. Exclusive production rights on a key compound – the primary ingredient of Novo Nordisk's Wegovy – is set to lapse in multiple countries in 2026. The Way Obesity Injections Work These medications mimick a biological compound to slow digestion, curb appetite and increase satiety so people reduce food intake. Patients usually see weight reduction in the initial weeks of beginning the weekly injections. Evidence indicates users may regain a significant portion a year later of halting the medication, when their usual appetite come back. Being carrying excess weight increases your likelihood for experiencing diseases, such as type 2 diabetes, cardiovascular issues, brain attack, and certain cancers. Obesity affects people in all nations and was linked to millions of fatalities worldwide in 2024, per the health agency.